Covidien Closes In On Varicose Vein Market With $440 Mil. VNUS Buy
This article was originally published in The Gray Sheet
Covidien will bolster its vascular business through the acquisition of varicose vein treatment marketer VNUS for $440 million
You may also be interested in...
Just one week after inking a deal to buy neurovascular product firm Reverse Medical, Covidien announced the purchase of another vascular device maker, Sapheon, which focuses on venous disease treatments.
Medtronic and Covidien have announced two deals each in the past week. The two firms are set to be combined by early next year under a megadeal announced in June.
Covidien says its large international operations will further accelerate ev3's fast-growing neurovascular and peripheral vascular businesses following its planned $2.6 billion acquisition of the endovascular firm